Abstract:1545 Purpose: To investigate the in vivo imaging characteristics of a novel tau tracer ((S)-1-(4-(6-(dimethylamino) naphthalen-2-yl)phenoxy)-3-fluoropropan-2-ol,18F-S16) in humans and evaluate its performance in identifying AD patients from healthy controls (HCs) as compared with 18F-THK5317. Methods: The study cohort consisted of 6 AD, 1 FTLD, 1 PSP, 1 DLB, 6 HCs and 2 young volunteers. While dynamic PET was performed over a period of 90 min after injection in 1 AD, 6 HCs and 2 young volunteers, static images were acquired in all subjects from 40 min to 60 min after tracers’ administration. All PET data were co-registered to the corresponding MRI data. The time-activity curves of standardized uptake value (SUV) and SUV ratios (SUVRs) were extracted from regions of interested based on the AAL atlas. Logan graphical analysis was performed for quantification of distribution volume ratios (DVRs). Cerebellum was used as the reference region to calculate DVRs and SUVRs. SUVRs derived from 70-90 min and 40-60min were regressed onto DVR to assess the quantitative accuracy of SUVR. Two-sample t-test was performed for the voxel-based analyses of both tracers to assess their uptake differences between populations. Results: Both tracers were distributed to the brain rapidly but the clearance of 18F-S16 was slower than 18F-THK5317 at 90 min acquisition. The AD patient showed increased cortical 18F-S16 binding (e.g., the medial temporal cortex), which was in contrast to a minimal accumulation of tracers seen in the young volunteers. Regional SUVR of both tracers’ time courses showed differences between groups in medial temporal cortex, lateral temporal cortex and occipital cortex. But the SUVR of 18F-S16 was still increasing at 90 min in very high-binding regions. Regression outcome of SUVR70-90min onto DVR performed better than SUVR40-60min. As to images, 18F-S16 displayed higher grey matter but lower white matter uptake than 18F-THK5317 in controls. In comparative studies, the cortical average SUVR of 18F-THK5317 was 1.32 ± 0.10 for AD versus 1.15 ± 0.05 for HCs (F = 5.91, P < 0.05), and for 18F-S16, that was 1.20 ± 0.08 versus 1.14 ± 0.06, respectively (F = 3.17, P < 0.05) (Table 1.). In voxelwised analysis, AD patients showed significant increased cortical 18F-THK5317 binding in diffused bilateral cortical regions; 18F-S16 displayed increased abnormal radioactive retention in bilateral lateral temporal cortex, occipital cortex and right frontal cortex (Figure 1.). The patterns of uptake of both tracers were similar in FLTD and PSP patients, which were observed increased radioactive retention in the anterior temporal cortex, the globus pallidus and midbrain, respectively. No obvious abnormal uptake was found in the DLB patient. Conclusions: A significant difference in 18F-S16 uptake between AD and HCs in cortical regions especially from 40-60 min after the tracer administration and elevated 18F-S16 retention was observed in where tau pathology frequently occurred in patients with PSP, thus 18F-S16 might be a promising tau-tracer for PET imaging. But quantification strategies for 18F-S16 need to be well evaluated with longer scan duration, such as 180min, in view of its slower clearance from brain.

PET Imaging of Translocator Protein (18 Kda) in a Mouse Model of Alzheimer's Disease Using N-(2,5-Dimethoxybenzyl)-2-18F-Fluoro-N-(2-Phenoxyphenyl)Acetamide

O2–11–05: Imaging Microglial Activation in a Mouse Model of Alzheimer's Disease Using PET/MRI and Ex Vivo Autoradiography

Pet Imaging For Dynamically Monitoring Neuroinflammation In App/Ps1 Mouse Model Using [F-18]Dpa714

PET Imaging for Dynamically Monitoring Neuroinflammation in APP/PS1 Mouse Model Using [18F]DPA714

Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [C-11]N '-MPB for visualization of 18 kDa TSPO in brain

Glial reactivity in a mouse model of beta-amyloid deposition assessed by PET imaging of P2X7 receptor and TSPO using [11C]SMW139 and [18F]F-DPA

Multi-target PET evaluation in APP/PS1/tau mouse model of Alzheimer’s disease

PET Imaging of Stroke-Induced Neuroinflammation in Mice Using [18F]PBR06

In Vivo [18F]SMBT‐1 Imaging of Reactive Astrocytes in Mouse Models of Alzheimer’s Disease ‐ Temporospatial Relationship with Amyloid, Tau and Microgliosis

PET Imaging of Neutrophils Infiltration in Alzheimer's Disease Transgenic Mice

Relationship Between Reactive Astrocytes, by [18F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer’s Disease

Relationship Between Reactive Astrocytes, by [18F]SMBT-1 Imaging, with Amyloid-Beta, Tau, Glucose Metabolism, and TSPO in Mouse Models of Alzheimer's Disease

Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline

Activated Microglia in the Early Stage of a Rat Model of Parkinson's Disease: Revealed by PET-MRI Imaging by [18F]DPA-714 Targeting TSPO

Post-Mortem validation of in vivo 18kDa Translocator Protein (TSPO) PET as a microglial biomarker

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

18F-PBR06 PET/CT Imaging for Evaluating Atherosclerotic Plaques Linked to Macrophage Infiltration

Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer's disease brains

In Vivo Imaging of Neurofibrillary Tau PET Radioligand 18F-S16 in Comparison with 18F-THK5317 in Alzheimer's Disease

In vivo Imaging With 18F-FDG- and 18F-Florbetaben-PET/MRI Detects Pathological Changes in the Brain of the Commonly Used 5XFAD Mouse Model of Alzheimer's Disease

Evaluation in Postmortem Human Alzheimer's Disease Brain Hippocampus and PET/CT Imaging in 5xFAD Transgenic Mice